Viking Therapeutics (VKTX) Stock News

Viking Therapeutics announced the initiation of Part 2 of a maintenance dosing study for VK2735, its dual GLP-1/GIP agonist. The trial will test oral and subcutaneous maintenance regimens after initial weight loss with weekly subcutaneous dosing. Results are expected in 2027.

Viking Therapeutics closed its upsized offerings of 9,035,714 common shares at $35.00 each and $258.75M in 2.00% convertible notes due 2032. Underwriters fully exercised options on both tranches. Net proceeds of ~$547.8M will fund VK2735 and VK3019 programs.

Shares of Viking Therapeutics (VKTX) dropped 12% premarket after the company priced an upsized common stock and convertible note offering. The offerings were increased from the original $200 million each to a larger deal, adding dilution and debt. Settlement is set for Friday.

Viking Therapeutics priced an upsized $500M offering of common stock and convertible senior notes. The offering will increase outstanding shares and add convertible debt, diluting existing holders.

Viking Therapeutics plans to offer $200 million of common stock and $200 million of convertible senior notes due 2032. Underwriters have 30-day options to buy up to an additional $30 million of each. Proceeds will fund clinical development of VK2735 and VK3019 programs and general corporate purposes. Shares fell 8.2% to $38.24 in after-hours trading.